Bibliography--Neural Sensitization: The Medical Key To Treatment
1 P Gregersen, “Chronic Toxic Encephalopathy in Solvent-exposed Painters in Denmark 1976-1980: Clinical cases and social consequences after a 5-year follow-up”, Am J of Ind Med , 11: 399-417, 1987.
2 LJ Machlin and A Bendich “Free radical damage: protective role of antioxidant nutrients”, FASEB J 6: 441-445, 1987.
3 S Moncada and J Bolanos, “Nitric oxide, cell bioenergetics and neurodegeneration”, J. Neurochem, 97:1676-1689, 2006.
4 JE Haley etal., “Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat”, Brain
Res 518:218-226, 1990.
5 M Lafon-Cazal etal., “Nitric oxide, superoxide and peroxynitrite: putative mediation of NMDA-induced cell death in cerebellar
cells”, Neuropharmacology 32:1259-1266, 1999.
6 IJ Reynolds and TG Hastings, “Glutamate produces production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation”, J. NeuroSci 15:3318-3327, 1995.
7 R Delfino, etal, “Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma”, Environ Health Persp, 114: 1736-1743, 2006.
8 JS Beckman, “The double edged role of nitric oxide in brain function and superoxide-mediated injury”, J.Dev Physiol 15:53-59, 1991.
9 M Lafon-Cazal etal. “NMDA-dependent superoxide production and neurotoxicity”, Nature 364:535-537, 1993.
10 JT Coyle and P Puttfarken, “Oxidative stress, glutamate and neuro generative disorders”, Science 262:689-695, 1993.
11 AY Sun YM Chen, “Oxidative stress and neurodegenerative disorders”, J Biomed Sci, 5: 401-14, 1998.
12 A Doble, “NMDA and neurodegenerative conditions (reviews)”, Pharmacol Ther 81:163-221, 1999.
13 VL Dawson and TM Dawson, “Nitric oxide neurotoxicity”, J Chem Neuroanat 10:179-190, 1996.
14 BC Albenzi, “Models of brain injury and alterations in synaptic neuroplasticity”, J. Neurosci Res 65:279-283, 2001.
15 JB Schultz etal., “The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases”, Mol Cell Biochem 174:171-184, 1997.
16 WG Mayhan, “Nitric oxide donor-induced increase in permeability of the blood-brain barrier”, Brain Res 866;101-108, 2000.
17 OG Khatsenko etal., “Nitric oxide is a mediator of the decrease in cytochrome p450-dependent metabolism caused by immunostimulants”, Proc Nat Acad Sci USA 90:11147-11151, 1993.
18 F Therese, etal, “Exhaled nitric oxide in children with asthma and short-term PM2.5 exposure in Seattle”, Environ Health Persp 113: 1791-1794, 2005.
19 JS Beckman and JP Crow, “Pathologic implications of nitric oxide, superoxide and peroxynitrite formation”, Biochem Soc Trans
21:330-333, 1993.
20 WA Pryor and GL Squadrito, “The chemistry of peroxynitrite: a product of the reaction of nitric oxide and superoxide”, Am J. Physiol 268:L699-L722, 1995.
21 A Novelli etal., “Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels become reduced”, Brain
Res 451:205-212, 1988.
22 M Hayakawa etal “Age-related oxygen damage and mutations in mitochondrial DNA in human hearts”, Biochem Biophys Res Commun 189: 979-985, 1992.
23 G Ziem, “Profile of patients with chemical injury and sensitivity”, Int J Toxicol 18:401-409, 1999.
24 F Ozguner, etal, “Mobile phone-induced myocardial oxidative stress: Protection by a novel antioxidant agent caffeic acidphenethyl ester, Toxicol and Indus Health 21: 223-230, 2005.
25 WD Willis, Role of neurotransmitters in sensitization of pain responses,” Ann NY Acad Sci 933;175-184, 2001.
26 SB McMahon etal., “Central excitability triggered by noxious inputs”, Current Opin Neurobiol 3:602-610, 1993.
27 VN Uversky, “Toxicants-induced animal models of Parkinsonism: Understanding the role of rotenone, maneb and paraquat in neurodegeneration”, Cell Tissue Res 318: 225-241, 2004.
28 M Thiruchelavam etal, “Developmental exposure to the pesticides paraquat and maneb and Parkinson’s disease phenotype”, Neurotoxicology 23: 621-633.
29 F Kamel etal, “Association of pesticide exposure with neurologic dysfunction and disease”, Environ Health Persp 112: 950-958,2004.
30 A Wu and Y Lin, Brain Res Mol Brain Res 110: 147, 2003.
31 A Beiruth etal, “Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action, “Env J Pharmacol 345: 233-245, 1998.
32 E Palazzo etal, “Interaction between vanilloid and glutamate receptors in the central modulation of nociception: Env J Pharmacol 439- 69-75, 2002.
33 H Kimata etal, “Effect of exposure to volatile organic compounds on plasma levels of neuropeptides, nerve growth factor and histamine in patients with chemical sensitivity”, Int J Hyg Environ Health 159-63, 2004.
34 WJ Meggs, “The toxic induction of asthma and rhinitis”, Clinical Toxicol 32: 487-501, 1994.
35 TR Garbe and H Yukama, “Common solvent toxicity: auto oxidation of respiratory redox-cyclers enforced by membrane
derangement”, Z Natur Forsch 56:483-491, 2001.
36 CJ Mattia etal., “Toluene-induced oxidative stress in several brain regions and other organs”, Mol Chem Neurophysiol 18:313-328, 1993.
37 WR Rogers etal, “A rat model of neurobehavioral sensitization to toluene,” Toxicol Indust Health 15: 356-369, 1999.
38 SR Thom etal “Neuronal nitric oxide synthase and n-methyl-d-aspartate neurons in experimental carbon monoxide poisoning”, Toxicol Applied Pharmacol 194: 280-295, 2004.
39 RE Lenga, Ed., Sigma-Aldrich Library of Chemical Safety Data. Sigma-Aldrich Corp, 1988.
40 GE Ziem, “Evaluation and Treatment of Patients with Chemical Injury and Sensitivity” Invited presentation at Aug 13-15, 2001. Conference sponsored by the National Institute of Environmental Health Sciences.
41 S Dubowski Adar etal, “Ambient and microenvironmental particles and exhaled nitric oxide before and after a group bus trip”,
Environ Health Persp, 115: 507-512, 2007.
42 A Barraza-Villarreal, etal, “Air pollution, airway inflammation, and lung function in a cohort study of Mexico City school children”
Environ Health Perspect 116: 832-838, 2008.
43 LTarantini, etal, “Effects of particulate matter on genomic DNA methylation content and iNOS promoter methylation”,
Environ Health Persp,117: 217-222, Feb 2009.
44 IN Roehm etal, “The influence of vitamin E on the lung fatty acids of rats exposed to ozone”, Archiv Environ Health 24: 237-242, 1972.
45 H Sprince etal, “Comparison of protection by L-ascorbic acid, L-cysteine, formaldehyde toxicity”, agents and actions 9: 407-414, 1979.
46 GA Pascoe etal, “A role of vitamin E in protection against cell injury, Env J Biochem 166: 241-247, 1987.
47 G Ziem, “Endocrine Changes in Patients with Chronic Illness Following Chemical Overexposure”, Invited presentation
at Conference on Chemical Injury, Fairfax, VA, October 3, 2003.
48 M Wolak, etal, “Kinetics and mechanism of the reversible binding of nitric oxide to reduced cobalamin B(12r) (Cob(II) alamin)” J Am Chem Soc 123: 9780-91, 2001.
49 D Zheng, etal, “Electrochemical and spectral studies of the reactions of aquacobalamin with nitric oxide and nitrite ion”, Inorgan Chem, 41: 2548-2555, 2002.
50 K Yamada, etal, Heterologous high level expression, purification, and enzymological properties of recombinant rat cobalamin-dependent methionine synthase,” J Bio Chem, 274: 35571-6, 1999.
51 D Z van Asselt etal. “Nasal absorption of hydroxycobalamine in healthy elderly adults”, Brit J Pharmacol 45: 83-86, 1998.
52 W B Slot, etal., “Normalization of plasma vitamin B12 by intranasal hydroxycobalamine in vitamin B12 deficient patients”, Gastroenterology 113: 430-433, 1997.
53 P H van der Kuy etal., “Hydroxycobalamine, a nitric oxide scavenger in the prophylaxis of migraine”, Cephalgia 22: 513-519, 2002.
54 JM Chang, etal “L alpha, 25 Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells”, J Lab Clin Med 143: 14-22, 2004.
55 Lefebvre d’ Hellencourt etal, “Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production in the EOC13 microglial cell line” J Neurosci Res 71: 575-582, 2003.
56 O Stanger, M Weger, “Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium”, Clin Chem Lab Med 41: 1444-1454, 2003.
57 CD Klassen etal, Editors, Cassarett and Doulls Toxicology: The Basic Science of Poisons, McGraw Hill, New York, NY, 2001.
58 W Watson, etal, “ A new role for glutathione: Protection of vitamin B12 from depletion by Xenobiotics”, Chem Res Toxicol
17: 1562-1567, 2004.
59 J Prousky, “The treatment of pulmonary diseases and respiratory-related conditions with inhaled (nebulized or aerosolized) glutathione)”, eCAM May 17, 2007.
60 R Buhl, etal Oxidant-protease interaction in the lung. Prospects for anti oxidant therapy. Chest 110:267S-272S, 1996.
61 C Bishop etal “A pilot study of the effect of inhaled reduced glutathione on the clinical status of patients with cystic fibrosis”, Chest 127: 308-317, 2005.
62 B Testa, M Mesolella, D Testa “ Glutathione in the upper respiratory tract”. Ann Otol Rhinol Laryngol 1995, 101:117-9.
63 Principals of Neurotoxicity Risk Assessment, US EPA, Fed Reg Aug 17, 1994.
64 S Oja etal, Modulation of glutamate receptor functions by glutathione” Neurochemistry International 37: 299-306, 2000.
65 T Konrad etal “Alpha-lipoic acid decreases serum lactate and pyruate and improves glucose effectiveness in lean and obese patients with type 2 diabetes”, Diabetes Care 22: 280-287, 1999.
66 L Packer etal, “Neuroprotection by the metabolic antioxidant alpha lipoic acid”, Free Radic Biol Med 22: 359-378, 1997.
67 D Ziegler etal, Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials”, Exp Clin Endocrinol Diabetes 107: 421-430, 1999.
68 A Smith etal, “Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress”, Corr Med Chem 11: 1135-1146, 2004.
69 H Moini etal., “Antioxidant and prooxidant activities of alpha lipoic acid and dihydrolipoic acid”, Toxicol Appl Pharm 182: 84-90, 2002.
70 A Bast, G Haenen, “Interplay between lipoic acid and glutathione in microsomal lipid peroxidation”, Biochim Biophys Acta 963: 558-561, 1988.
71 P Porras etal., “Glutaredioxins catalyze the reduction of glutathione by dihydrolipomide with high efficiency”, Biochem Biophys Res Commun 295: 1046-1051, 2002.
72 S Hustad etal, “Riboflavin, flavin mononucleotide, flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation”, Clin Chem 48; 1571-1577, 2002.
73 A Prentice, C Bates, “A biochemical evaluation of the erythrocyte glutathione reductase (EC1.6.4.2) test for riboflavin status. Dose response relationships in chronic marginal deficiency”, Brit J Nutr 45: 53-65, 1981.
74 J Schoenen etal, “Effectiveness of high-dose riboflavin in migraine prophylaxis”, Dept of Neurology, University of Liege, Belgium.
75 M Jones, “Chronic neuropathic pain: pharmacological in the new millennium”, Internat J Pharmaceutical Compounding, Jan-Feb 2000.
76 M Ghyczy, M Boros, “Electrophilic methyl groups present in the diet ameliorate states induced by reductive and oxidative stress”, Brit J Nutr 85: 409-414, 2001.
77 S Christen etal, “Gamma-tocopherol traps mutagenic electrophiles such as NOx and complements alpha-tocopherol: Physiologic implications” Proc Natl Acad Sci 94: 3217-3222, 1997.
78 K Wagner etal, “Gamma-tocopherol-an underestimated vitamin” J Nutr 122: 2440-2446, 1992.
79 E Giovannucci, Y-Tocopherol: a new player in prostate cancer prevention” J Natl Cancer Inst, 92: 1966-1967, 2000
80 GA Pascoe, etal, “A role in vitamin E in protection against cell injury, maintenance of intracellular glutathione precursors
and biosynthesis”, Eur J Biochem 166: 241-247, 1987.
81 JN Roehm, etal, Antioxidants vs lung disease”, Arch Intern Med 128: 88-93, 1971.
82 BL Fletcher and AL Tappel, “Protective effects of dietary tocopherol in rats exposed to toxic levels of ozone and nitrogen dioxide.” Env Research 6: 165-175, 1973.
83 J Feher etal, “Oxidative stress in the liver and biliary tract diseases”, Scand J Gastroenterol 228: S38-S46, 1998.
84 LO Koltz, H Sies, “Defenses against peroxynitrites: seleno compounds and flavinoids”, Toxicol Lett 140-141: 125-132, 2003.
85 F Cohen-Boulakia et al, “In vivo sequential study of skeletal muscle capillary fragility in diabetic rats: effects of anthocyanosides”. Metabolism 49: 880-885, 2000.
86 M Perossini etal, “Diabetic and hypertensive retinopathy therapy with vaccinium myrtillus anthocyanosides: a double blind, placebo-controlled trial”, Ann Ofthalm Clin Ocul 113: 1173-1190, 1987.
87 JO Moskaug, etal, “Dietary Polyphenols and Health: Proceedings of the 1st International Conference on Polyphenols and Health”, Am J Clin Nutr 81: 277S-283S, 2005.
88 K Kaneda etal., “The effects of B vitamins on glutamate-induced neurotoxicity in retinal cultures”, Env J Pharmacol 322:259-264, 1997.
89 N Kocak-Toker, etal, “Peroxynitrite induced decrease in Na+, K+-ATPase activity is restored by taurine.” World Journal of Gastroenterology. 11: 3554-3557, 2005.
90 D Bagchi etal, “Oxygen free radical scavenging abilities of vitamins C, E and a grape seed proanthocyanidin in vitro”, Free Radical Biol Med 16: 845-50, 1994.
91 T Yokozawa etal, “(-)-Epigallocatechin 3-0-gallate ameliorates the damage related to peroxynitrite production by mechanisms distinct from other free radical inhibitors”, Xenobiotica 33: 913-25, 2003.
92 A Higuchi etal, “Inhibitory activity of epigallocatechin gallate (EGCg) in paraquat-induced microsomal lipid peroxidation”, Int Immunopharmacol 2: 849-55, 2002.
93 E Alvarez etal, “Effect of (-)-epigallocatechin-3-gallate on respiratory burst of rat macrophages”, Biosci Biotechnol Biochem 63: 1621-1623, 1999.
94 Food Research Institute, Mitsui Norin Co Ltd, “Radical scavenging activity of tea catechins and their related compounds”, J Agri Food Chem 47: 425-431, 1999.
95 G Muzes etal, “Effect of the bioflavinoid silimarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme”, Tokai J Exp Clin Med 15: 129-134, 1990.
96 J Feher etal, “In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase activity in patients”. Tokai J Exp Clin Med, 15: 129-134, 1990.
97 A Eldrissi, E Trenkner, “Taurine as a modulator of excitatory and inhibitory neurotransmission”, Neurochem Res 29: 189-197, 2004.
98 SA Sulaiman etal, “Kinetic studies on the inhibition of GABA-T by gamma-vinyl GABA and taurine”, J Enzyme Inhib Med Chem 18:297-301, 2003.
99 N del Olmo etal, “Taurine activates GABA (A) but not GABA (B) receptors in rat hippocampal CA1 area”, Brain Res 864: 298-307.
100 H Wang etal., “ Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy”, Arch Dis Child 90: 512-515, 2005.
101 J Liu etal “Comparison of the effects of L-carnitine and acetyl-L-carnitine”, Ann NY Acad Sci 1033: 117-131, 2004.
102 A Guyton and J Hall, Editors, Textbook of Medical Physiology, WB Saunders Co., Philadelphia, PA.
103 L Packer etal, “Neuroprotection by the metabolic antioxidant alpha-lipoic acid”, Free Radio Biol Med 22: 359-378, 1997.
104 M Trujillo etal, “Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic acid and dihydrolipoic acid”, Free Radic Biol Med 39: 279-288, 2005.
105 A Dlugosz, E Sawicka, “The chemoprotective effect of coenzyme Q10 on lipids in the paint and lacquer industry workers”, Int J Occup Med Environ Health 11:153-153.
106 MC Linder, Editor, Nutritional Biochemistry and Metabolism with Chemical Applications, 2nd Edition, Appleton and Lange, Norwalk, CT, 1991.
107 RK Murray etal, editors, Harper’s Biochemistry, Appleton and Lange, 1993.
108 MI Gurr and AT James, Editors, Lipid Biochemistry, Chapman and Hall, NY, 1980.
109 W Kematsu etal “Docosahexanoic acid and nitric oxide and inducible nitric oxide synthase expression…” Free Rad Biol Med 34: 1006-1016, 2003.
110 T Ohata etal, “Suppression of nitric oxide production in lipopohycaccharide-stimulated macrophage cells by omega 3 polyunsaturated fatty acids J Cancer Res 88: 234-237, 1997.
111 M Takahashi etal, “Fish oil feeding alters live gene expression to defend against PPAR activation and ROS production”, Am J Physiol Gastroint Liver Physiol 282: 338-348, 2002.
Back to: New Treatment for Chemical Injury and Chemical Sensitivity
Home-
|
